Annotation Detail
Information
- Associated Genes
- JAK2
- Associated Variants
- JAK2 SSBP2-JAK2
- Associated Disease
- B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
- Source Database
- CIViC Evidence
- Description
- The SSBP2-JAK2 fusion was identified in a 14 yo male with Ph-like B-ALL, a t(5;9)(q12;p1?3), and a WBC of 160,000. Following 4-drug induction therapy the patient had an MRD of 5.5%, indicating a poor response. After two additional weeks of induction, intermittent ruxolitinib was added to his regimen and a bone marrow performed 3 weeks after the addition of ruxolitinib showed 1% MRD. Following consolidation, the bone marrow showed 0.3% MRD.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7257
- Gene URL
- https://civic.genome.wustl.edu/links/genes/28
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2661
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like
- Evidence Direction
- Supports
- Drug
- Ruxolitinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25207766
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ruxolitinib | Sensitivity | true |